Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,040 from $766 and keeps an Overweight rating on the shares. The firm’s model now incorporates six new pipeline indications for Vyvgart and one new pipeline indication for empasiprubart, capturing an opportunity it sees being “underappreciated” by the Street, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Vor Bio appoints Khan as Chief Medical Affairs Officer
- Argenx price target raised to $882 from $797 at Stifel
- Argenx Completes Phase 1 Study on ARGX-109: Key Insights for Investors
- Argenx’s Strategic Diversification and Promising Pipeline Highlighted by Buy Rating
- Argenx assumed with a Buy at Truist